Search results
Results from the WOW.Com Content Network
There is plenty to like about Merck (NYSE: MRK). It is one of the largest pharmaceutical companies and the owner of the world's current best-selling drug, cancer medicine Keytruda. Merck generates ...
The next few years might get bumpy for the pharmaceutical giant, but the longer term looks better.
Even with that growth, the stock still trades at a fairly modest valuation. Its stock price is up 5.3% this year, compared with 16% growth for the S&P 500. Why isn't Merck's stock doing better in ...
Keytruda has been the best-selling medicine in the world since last year, when it generated $25 billion in sales. Merck's total revenue for the year was $60.1 billion, so Keytruda accounted for ...
Before you buy stock in Merck, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Merck wasn’t one ...
Buying back Merck stock is clearly the safer route, but buying a company or three to boost its drug offerings has more potential. ... The Fool tackles all of the company's moving parts, its major ...
For premium support please call: 800-290-4726 more ways to reach us
Merck (MRK) closed at $86.05 in the latest trading session, marking a -0.69% move from the prior day.